Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Henning Schade"'
Autor:
David H. Vesole, Jesus Berdeja, Jeffrey Matous, Suzanne Trudel, Henning Schade, Pamela Munster, Savannah Berkeley, Benjamin Sun, Tom Martin
Publikováno v:
HemaSphere, Vol 7, p e5189693 (2023)
Externí odkaz:
https://doaj.org/article/b99d3d74d83b402b91466cabb63936d9
Autor:
Al-Ola Abdallah, Andrew J Cowan, Xavier Leleu, Cyrille Touzeau, Brea Lipe, Eva Medvedova, Caitlin Costello, Jens Hillengass, P. Leif Bergsagel, Raya Mawad, Henning Schade, Daniel Morillo Giles, Albert Oriol, Yifah Yaron, Patrick P Ng, Sumit Madan
Publikováno v:
Blood. 140:7284-7285
Autor:
Luke St. John, Tara K. Gregory, Patricia Wagner, Sarah Meissner, Henning Schade, Scott Irvin Bearman, Richard A. Nash, Marcello Rotta, Jeffrey V. Matous, Alireza Eghtedar, Michael Timothy Tees, Michael B. Maris, Luke Mountjoy
Publikováno v:
Journal of Clinical Oncology. 40:e19047-e19047
e19047 Background: Human Leukocyte Antigen (HLA) typing is a necessary but expensive process to identify suitable donors for allogeneic hematopoietic cell transplantation (HCT) for the treatment of bone marrow disorders and hematologic malignancies.
Autor:
Ravi Vij, Henning Schade, Suzanne Trudel, Alice C. Chang, Jiangeng Huang, Divya Samineni, Teiko Sumiyoshi, Jennifer Tsai, Tiffany Wong, Simon J. Harrison
Publikováno v:
Journal of Clinical Oncology. 40:TPS8069-TPS8069
TPS8069 Background: Treatment of relapsed/refractory (R/R) multiple myeloma (MM) is challenging, especially in later lines where drug resistance reduces therapeutic options and remission duration. Prognosis is poor (estimated survival: < 1 year) for
Publikováno v:
Blood. 138:2455-2455
Introduction: Autologous stem cell transplants (ASCT) are standard of care for patients with primary refractory or recurrent Hodgkin lymphoma (HL). While transplant results in cure for some patients, others relapse and succumb from their disease. Stu
Autor:
Henning Schade, Sumit Madan, Xavier Leleu, Jens Hillengass, Liping Laura Sun, William I. Bensinger, Rajneesh Nath, Andrew J. Cowan, Caitlin Costello, Brea Lipe, Al-Ola Abdallah, Eva Medvedova
Publikováno v:
Blood. 138:1654-1654
Background B cell maturation antigen (BCMA) is a clinically validated target for multiple myeloma (MM) based on its restricted expression profile and potential functional role in promoting MM cell survival. HPN217 is a BCMA-targeting T cell engager d
Autor:
Jeffrey Matous, Julie Murphy, Peter A. McSweeney, Henning Schade, Tara K. Gregory, Michael B. Maris, Marcello Rotta, Michael Tees, T. Gooley, Luke Mountjoy, Richard A. Nash, Alireza Eghtedar
Publikováno v:
Transplantation and Cellular Therapy. 27:S226-S227
Autor:
Dexiang Gao, Brian M. Freed, C. Preston Neff, Brent E. Palmer, Jonathan A. Gutman, Sharon Sen, Henning Schade
Publikováno v:
Biology of Blood and Marrow Transplantation. 22:2172-2179
Excessive or persistent programmed death 1 (PD-1) expression on virus- or tumor-specific T cells during chronic viral infection or malignancy has been associated with impaired immune control. To assess the role of the PD-1 pathway in allogeneic stem
Autor:
Lisa Knapp, Eva Medvedova, Henning Schade, Rajneesh Nath, Sumit Madan, Liping Laura Sun, Lemon Bryan D
Publikováno v:
Blood. 136:10-10
Background B cell maturation antigen (BCMA) has emerged as a promising target for multiple myeloma (MM) therapies based on its restricted expression profile and functional role in promoting MM cell survival. Some of these BCMA targeting molecules, in
Autor:
Kathy Hogan Edwards, Amanda Littleton, Molly Schneider, Henning Schade, Cindy Kramer, Milos N. Budisavljevic, Yubin Kang, Saurabh Chhabra, Coleen Butcher, Robert K. Stuart, Luciano J. Costa
Publikováno v:
Transfusion. 54:3131-3137
Background Compared with growth factor (G) alone, the combination of G with plerixafor (G + P) increases peripheral blood CD34+ count (PB-CD34+) and improves CD34+ collection yield (yCD34+) in multiple myeloma and lymphoma patients undergoing autolog